Elizabeth Aronson Walks Through the Data Supporting Elranatamab Approval in Multiple Myeloma
Elizabeth Aronson, MSN, FNP-BCN, OCN, shares what stood out to her about the phase 2 MagnetisMM-3 trial assessing elranatamab in multiple myeloma.
Ambulation Improves Frailty Scores in Patients With Multiple Myeloma
Resistance training and walking can be beneficial for patients with multiple myeloma.
PVd Confers a Small OS Benefit to Patients With Relapsed/Refractory Multiple Myeloma
Patients who received pomalidomide, bortezomib, and dexamethasone achieved a median overall survival of 35.6 months compared with 31.6 months among patients treated with bortezomib and dexamethasone.
Real-World Experiences With Teclistamab Are Comparable To Clinical Trial Reports
In a single-center retrospective analysis, the median progression-free survival among patients with multiple myeloma treated with teclistamab was 4.7 months.
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Patients with EGFR-mutated non–small cell lung cancer had a median event-free survival of 30.8 months in the durvalumab arm and 19.6 months in the placebo arm.
Oncology Drug Crash Course: Elacestrant (Orserdu)
Kristine Gibbons, RN, OCN, who is a Nurse Trainer at Florida Cancer
Specialists & Research Institute, provides an in-depth look at elacestrant in a downloadable fact sheet.
Genetic Testing Is Becoming an Important Conversation in Metastatic Prostate Cancer
Meredith Donahue, APRN-BC, discusses emerging therapies in metastatic prostate cancer.
How To Use Inclusive Language When Caring for Transgender Persons With Cancer
Stephanie Russell, DNP, AGNP-C, highlights the importance of gender-neutral language in the oncology environment.
Is It Time to Rethink the Bell Ringing Ceremony in Cancer Care?
Lindsey Zinck, PhD, RN, OCN, NEA-BC, and Melania Zisa, RN, BSN, OCN, discuss why it may be time to make the bell ringing ceremony a more inclusive celebration in cancer care.
Bosutinib Is Approved for Pediatric Ph+ CP–Chronic Myeloid Leukemia
The FDA has approved bosutinib to treat pediatric patients with Philadelphia chromosome–positive, chronic-phase chronic myelogenous leukemia.
Opinion: We Need to Advocate for Patients During the Chemotherapy Shortage
Congress needs to enact legislation that ensures chemotherapy shortages become a thing of the past.
Prompt Intervention During Infusion-Related Reactions Is Essential
Maura Price, MSN, RN, AOCNS, discusses common infusion-related reactions and the principles of desensitization.
Benmelstobart Plus Anlotinib Shows Survival Benefit in ES-SCLC
The benmelstobart combination reduced the risk of death by 39% vs placebo plus chemotherapy in patients with extensive-stage small cell lung cancer.
Perioperative Durvalumab Plus Chemo Boosts pCR, EFS in Resectable NSCLC
The pathological complete response among patients who received durvalumab plus chemotherapy was 17.2% vs 4.3% in the placebo plus chemotherapy arm.
Interim PET2 Scans May Be Redundant in Frontline Brentuximab Vedotin Regimens Treatments for Hodgkin Lymphoma
Data suggest that frontline treatment brentuximab vedotin elicits superior outcomes in patients with Hodgkin Lymphoma, regardless of PET2 results.
FDA Launches Priority Review of Belzutifan for Previously Treated Advanced RCC
The FDA has granted belzutifan priority review designation based on data from the phase 3 LITESPARK-005 trial.
Are At-Home Genomic Tests Such as 23andMe Ethical?
Cheryl VerStrate, DNP, AGPCNP-BC, OCN, explains the pitfalls with at-home genomic tests and why nurses must be ready to talk to their patients about genetic counseling.
Oncology Nurses Need a ‘Creative Outlet’
Ellen Miller, MSN, FNP-BC, an oncology nurse practitioner, explains how she uses wreath-making to maintain a healthy work-life balance.
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Findings from the PACIFIC-R trial showed that patients with EGFR-mutated non-small cell lung cancer experienced shorter progression-free survival with durvalumab than patients with EGFR-wildtype disease.
Immunotherapy-Based Regimens Are Associated With OS Advantage in HCC
Immuno-oncology regimens were linked with improved long-term survival among patients with hepatocellular carcinoma.
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
Quizartinib plus standard intensive induction and consolidation therapy was associated with longer survival rates in patients with FLT3-ITD–positive acute myeloid leukemia.
Connecting Patients To Better Dental Services is a Top Priority in Head and Neck Cancer Navigation
Shawna Douglas, a head and neck nurse navigator, weighs in on the unique needs of this patient population.
2 Years of Ovarian Suppression May Be Optimal for Select Patients With ER+ Breast Cancer
For patients with ER-positive breast cancer who remain premenopausal—or regain ovarian function—following chemotherapy, 2 years of ovarian suppression may be beneficial.
PARP Inhibitors May Be a Promising Treatment Strategy in Advanced Uterine Leiomyosarcoma
Kjersten Dosumu, DNP, MS, AGPCNP-BC, explains why investigators are optimistic about treating uterine leiomyosarcoma with olaparib and temozolomide.
Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC
The confirmed objective response rate with repotrectinib was 79% among tyrosine kinase inhibitor (TKI)-naïve patients and 38% among TKI-pretreated patients.
Osimertinib May Be More Effective in Frontline EGFR+ NSCLC When Combined With Chemo
The median progression-free survival was 25.5 months with osimertinib plus chemotherapy and 16.7 months with osimertinib alone.
FDA Approves Momelotinib to Treat Myelofibrosis With Anemia
The FDA has approved momelotinib (Ojjaara) for the treatment of adult patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis, and anemia.
Inflammatory Breast Cancer Is Often Missed, But May Now Be Easier To Diagnose
Ryan Tamargo, NP, AONCP, highlights how a new diagnostic tool can help improve accurate inflammatory breast cancer diagnoses.
Sacituzumab Govitecan/Pembrolizumab Shows Early Antitumor Activity in Metastatic NSCLC
The objective response rate with sacituzumab govitecan plus pembrolizumab was 56%.
Patritumab Deruxtecan Elicits Durable Responses in Pretreated EGFR-Mutated NSCLC
Patrimumab deruxtecan garnered a 29.8% overall response rate in pretreated patients with EGFR-mutated non–small cell lung cancer.
2 Clarke Drive Cranbury, NJ 08512